Waystar Q1 Beats on Growth and Margins, But Valuation and Leverage Loom

What happened

Waystar reported strong Q1 2026 results with revenue up 22% YoY to $313.9M, net income of $43.3M and adjusted EBITDA margin of 43%, reflecting the profitability inflection flagged in the DeepValue report. The company continues to benefit from secular tailwinds in healthcare payment software and its sticky, recurring revenue model. Despite the strong operational performance, the stock remains richly valued at ~58x trailing earnings and ~13.5x EV/EBITDA with net debt/EBITDA of 3.5x. The Q1 results provide evidence of the business's earnings power, but the high leverage and valuation leave little room for error. Investors should watch for sustained growth, deleveraging, and successful integration of the Iodine acquisition to justify the premium multiples.

Implication

The Q1 beat confirms the operational improvement and growth trajectory, but the stock's premium multiples already reflect high expectations. The adjusted EBITDA margin of 43% and net income margin of 14% demonstrate operating leverage and the transition to profitability. However, with net debt/EBITDA at 3.5x and interest coverage of 3.3x, the balance sheet remains a risk, especially if rate cuts are delayed. The future path depends on sustaining double-digit revenue growth, expanding margins, and reducing leverage through FCF generation. A pullback toward the DCF-implied value (~$22) would offer a better risk/reward, but for now, a 'wait' stance is warranted.

Thesis delta

The Q1 results confirm the profitability inflection and strong revenue growth, but the thesis remains unchanged: strong business quality but expensive valuation and leverage. The delta is that near-term execution is on track, reducing downside risk from operational disappointment, but the upside is limited at current prices. The watch items shift from 'can they deliver growth?' to 'can they delever and sustain margins?'